Certified Global Research Member

Key Questions Answered

Global Market Outlook
In-depth analysis of global and regional trends
Analyze and identify the major players in the market, their market share, key developments, etc.
To understand the capability of the major players based on products offered, financials, and strategies.
Identify disrupting products, companies, and trends.
To identify opportunities in the market.
Analyze the key challenges in the market.
Analyze the regional penetration of players, products, and services in the market.
Comparison of major playersâ€™ financial performance.
Evaluate strategies adopted by major players.
Recommendations

Why Choose Market Research Future?

Vigorous research methodologies for specific market.
Knowledge partners across the globe
Large network of partner consultants.
Ever-increasing/ Escalating data base with quarterly monitoring of various markets
Trusted by fortune 500 companies/startups/ universities/organizations
Large database of 5000+ markets reports.
Effective and prompt pre- and post-sales support.

Lung Cancer Companies

Lung cancer is a devastating disease that continues to be a major global health concern. As one of the leading causes of cancer-related deaths worldwide, the search for effective lung cancer therapeutics has prompted numerous pharmaceutical and biotechnology companies to invest heavily in research and development.

Lung Cancer Therapeutics Key Companies

Latest Lung Cancer Therapeutics Companies Update:

AstraZeneca's Tagrisso shows promising results in a Phase III trial: This trial demonstrated Tagrisso's efficacy in treating EGFR-mutated non-small cell lung cancer (NSCLC) with less brain metastases compared to other targeted therapies.

Mirati Therapeutics' investigational drug adavosertib receives Breakthrough Therapy designation from the FDA: This designation recognizes the potential of adavosertib for treating KRAS G12C-mutated NSCLC, a previously difficult-to-treat mutation.

Roche acquires Blueprint Medicines for $3.9 billion: This acquisition strengthens Roche's lung cancer portfolio by adding Blueprint's expertise in targeted therapies for RET-driven cancers, including some lung cancers.

Merck & Co. partners with BeiGene to develop and commercialize tislelizumab: This collaboration expands access to tislelizumab, a promising PD-1 inhibitor, for treating lung cancer and other solid tumors worldwide.

List of Lung Cancer Therapeutics Key companies in the market

Hoffmann-La Roche Ltd (Switzerland)

Novartis AG (Switzerland)

Pfizer (U.S.)

Bristol-Myers Squibb (U.S.)

Eli Lilly and Company (U.S.)

Sanofi (France)

Lung Cancer Market Highlights:

Lung Cancer Market Size

Lung Cancer Market Trends

Lung Cancer Market Analysis

Lung Cancer Market Share

Lung Cancer Market Highlights:

Lung Cancer Market Trends

Lung Cancer Market Analysis

Lung Cancer Market Share

Lung Cancer Companies

Leading companies partner with us for data-driven Insights

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
	Single User	$ 4,950
	Multiuser License	$ 5,950
	Enterprise User	$ 7,250
Compare Licenses

Tailored for You

Dedicated Research on any specifics segment or region.
Focused Research on specific players in the market.
Custom Report based only on your requirements.
Flexibility to add or subtract any chapter in the study.
Historic data from 2014 and forecasts outlook till 2040.
Flexibility of providing data/insights in formats (PDF, PPT, Excel).
Provide cross segmentation in applicable scenario/markets.